A selective inhibitor of oncogenic JNK signalling perturbs metastatic outgrowth of triple-negative breast cancer through metabolic blockade
Latham, S. L.; O'Donnell, Y. E.; Girgis-Cook, O.; Clearwater, M. S.; Bryce, N. S.; Mok, E.; Lynn, S. A.; Ni, J.; Alfred, S.; Leong, K. H.; Quek, L.-e.; Murphy, K.; Pantarelli, C.; Dragutinovic, I.; Naeini, M.; Thiel, C.; Cadell, A.; Phimmachanh, M.; Sharma, R.; Millar, E.; Han, J. Z.; Hastings, J. F.; Koehler, M.; Brummer, T.; Young, A.; O'Toole, S.; Oakes, S.; Hardeman, E.; Lock, J.; Kolch, W.; Taft, M. H.; Nobis, M.; Goldstein, L.; Timpson, P.; Parker, B. L.; Holst, J.; Gunning, P. W.; Cox, T. R.; Morris, J. C.; Croucher, D. R.
Show abstract
Although c-Jun N-terminal Kinase (JNK) represents an attractive anti-cancer target, its pleiotropic functionality limits the use of direct JNK inhibitors. Here, we identify a distinct subcellular pattern of JNK activity as a therapeutic vulnerability in breast cancer, where cytoplasmic JNK activity predicts poor survival outcomes, is elevated in triple-negative breast cancers (TNBC) and is essential for metastatic outgrowth. Mechanistic analyses reveal cytoplasmic JNK acts through multiple mechanisms, with downstream targets involved in cellular metabolism and cytoskeletal regulation. On this basis, we leveraged actin-based phenotypic drug-screening and identified K12, an indirect but selective inhibitor of cytoplasmic JNK that blocks TNBC metastatic outgrowth in vivo. We reveal that K12 inhibits glutaminase-1 and the pyruvate dehydrogenase complex, and that this poly-pharmacology overcomes pyruvate anaplerosis, a known resistance mechanism of existing glutaminase inhibitors. These findings demonstrate the potential of selectively targeting the oncogenic function of JNK, offering new treatment options for early-stage metastatic TNBC.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Androgen receptor inhibition induces metabolic reprogramming and increased reliance on oxidative mitochondrial metabolism in prostate cancer 95%
- eIF3d and eIF3e mediate selective translational control of hypoxia that can be inhibited by novel small molecules 95%
- Drug-induced eRF1 degradation promotes readthrough and reveals a new branch of ribosome quality control 95%
Similar papers in this journal
- Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases 95%
- Chemoproteomics reveals immunogenic and tumor-associated cell surface substrates of ectokinase CK2α 95%
- Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors 95%
Similar papers in this journal
- Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells 95%
- Colon Cancer Cells Evade Drug Action by Enhancing Drug Metabolism 94%
- EWS::FLI1-DHX9 interaction promotes Ewing sarcoma sensitivity to DNA topoisomerase 1 poisons by altering R-loop metabolism 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.